Bristol-Myers Squibb: all 2,184 studies

Page 5 of 22. Open to participants first (162), then studies with results posted, then the rest; newest registration first within each.

• Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced MelanomaCompletedNCT02599402Phase 3Results posted
• An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.CompletedNCT02598960Phase 1/2Results posted
• Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's DiseaseTerminatedNCT02596893Phase 3Results posted
• An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell CarcinomaCompletedNCT02596035Phase 4Results posted
• A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid TumorsCompletedNCT02593786Phase 1/2Results posted
• Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)CompletedNCT02592798Phase 2Results posted
• An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin LymphomasCompletedNCT02581631Phase 1/2Results posted
• An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 MutationCompletedNCT02577406Phase 3Results posted
• A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple SclerosisCompletedNCT02576717Phase 3Results posted
• An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular CarcinomaCompletedNCT02576509Phase 3Results posted
• A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02574078Phase 1/2Results posted
• A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process CCompletedNCT02564497Phase 1Results posted
• Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid ArthritisCompletedNCT02557100Phase 4Results posted
• Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT02546986Phase 2Results posted
• A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. DacarbazineCompletedNCT02545075Phase 3Results posted
• Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in METCompletedNCT02544633Phase 2Results posted
• A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02538965Phase 2Results posted
• An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based ChemotherapyCompletedNCT02538666Phase 3Results posted
• Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)TerminatedNCT02535364Phase 2Results posted
• An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative ColitisCompletedNCT02531126Phase 3Results posted
• Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's DiseaseCompletedNCT02531113Phase 2Results posted
• A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)TerminatedNCT02509039Phase 1Results posted
• Effects of Abatacept in Patients With Early Rheumatoid ArthritisCompletedNCT02504268Phase 3Results posted
• A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological DisordersCompletedNCT02494258Phase 2Results posted
• An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated TumorsCompletedNCT02488759Phase 1/2Results posted
• Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung CancerCompletedNCT02481830Phase 3Results posted
• An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02477826Phase 3Results posted
• Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid TumorsTerminatedNCT02472977Phase 1/2Results posted
• Apixaban for the Acute Treatment of Venous Thromboembolism in ChildrenCompletedNCT02464969Phase 4Results posted
• Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative ColitisCompletedNCT02435992Phase 3Results posted
• Study of BMS-986158 in Subjects With Select Advanced CancersCompletedNCT02419417Phase 1/2Results posted
• A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the HeartCompletedNCT02415400Phase 4Results posted
• A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)CompletedNCT02413372Phase 2Results posted
• An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLCCompletedNCT02409368Phase 2Results posted
• A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT02406742Phase 1/2Results posted
• Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV MelanomaCompletedNCT02388906Phase 3Results posted
• A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder CancerCompletedNCT02387996Phase 2Results posted
• Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With FulvestrantTerminatedNCT02374099Phase 2Results posted
• A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With AsparaginaseCompletedNCT02369653Phase 3Results posted
• A Study of BMS-986148 in Patients With Select Advanced Solid TumorsTerminatedNCT02341625Phase 1/2Results posted
• Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and BevacizumabCompletedNCT02330562Phase 1/2Results posted
• An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by ItselfCompletedNCT02320058Phase 2Results posted
• Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated CirrhosisCompletedNCT02319031Phase 3Results posted
• An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT02305563Phase 1/2Results posted
• Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)CompletedNCT02301143Phase 2Results posted
• Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating DasatinibCompletedNCT02297139Phase 2Results posted
• Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)CompletedNCT02294058Phase 3Results posted
• Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2CompletedNCT02289456Phase 2Results posted
• Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell LymphomaCompletedNCT02285062Phase 3Results posted
• Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic SyndromesCompletedNCT02281084Phase 2Results posted
• Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy NaiveCompletedNCT02279862Phase 2Results posted
• Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and CarboplatinCompletedNCT02279732Phase 3Results posted
• Study to Evaluate Safety and Efficacy in Adult Subjects With ITPCompletedNCT02273960Phase 1/2Results posted
• Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 MutationCompletedNCT02273739Phase 1/2Results posted
• Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in JapanCompletedNCT02272803Phase 2Results posted
• Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal CarcinomaCompletedNCT02269943Phase 2Results posted
• Safety and Efficacy Study of a Biologic to Treat Systemic Lupus ErythematosusCompletedNCT02265744Phase 2Results posted
• An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's LymphomaTerminatedNCT02253992Phase 1/2Results posted
• Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung CancerCompletedNCT02250326Phase 2Results posted
• BMS-986012 in Relapsed/Refractory SCLCCompletedNCT02247349Phase 1/2Results posted
• Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)CompletedNCT02231749Phase 3Results posted
• A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.CompletedNCT02185040Phase 2Results posted
• Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)CompletedNCT02181738Phase 2Results posted
• Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)CompletedNCT02175966Phase 2Results posted
• A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1CompletedNCT02170727Phase 3Results posted
• Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma PatientsCompletedNCT02159365Phase 2Results posted
• Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy ParticipantsCompletedNCT02159352Phase 1Results posted
• A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart FailureCompletedNCT02157506Phase 2Results posted
• A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)CompletedNCT02156804Phase 2Results posted
• A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial FibrillationTerminatedNCT02156076Phase 2Results posted
• Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the ElderlyCompletedNCT02151149Phase 4Results posted
• Regimen Optimization StudyCompletedNCT02137239Phase 2Results posted
• Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)CompletedNCT02105636Phase 3Results posted
• Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal CancerCompletedNCT02103062Phase 2Results posted
• Bioavailability of Apixaban Crushed TabletCompletedNCT02101112Phase 1Results posted
• A Study to Evaluate BMS-986036 in Obese Adults With Type-2 DiabetesCompletedNCT02097277Phase 2Results posted
• A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult SubjectsCompletedNCT02074358Phase 1Results posted
• A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy RegimenCompletedNCT02066636Phase 3Results posted
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell MalignanciesCompletedNCT02061761Phase 1/2Results posted
• A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadCompletedNCT02060188Phase 2Results posted
• Efficacy and Safety Study of Ozanimod in Relapsing Multiple SclerosisCompletedNCT02047734Phase 3Results posted
• An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)CompletedNCT02041533Phase 3Results posted
• Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)CompletedNCT02038946Phase 2Results posted
• Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)CompletedNCT02038933Phase 2Results posted
• Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy SubjectsCompletedNCT02034591Phase 1Results posted
• Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy SubjectsCompletedNCT02034578Phase 1Results posted
• Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy SubjectsCompletedNCT02034565Phase 1Results posted
• Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCVCompletedNCT02032901Phase 3Results posted
• A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.CompletedNCT02032888Phase 3Results posted
• Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver TransplantCompletedNCT02032875Phase 3Results posted
• Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung CancerCompletedNCT02027428Phase 3Results posted
• A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma PatientsCompletedNCT02017717Phase 3Results posted
• Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic CancerCompletedNCT02017015Phase 2Results posted
• A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid LeukemiaCompletedNCT02011945Phase 1Results posted
• Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT02011113Phase 2Results posted
• A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on HemodialysisCompletedNCT01999582Phase 2Results posted
• ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple MyelomaTerminatedNCT01997840Phase 1/2Results posted
• Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.CompletedNCT01996865Phase 3Results posted
• Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude DualCompletedNCT01995266Phase 3Results posted
• Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma PatientsCompletedNCT01990859Phase 2Results posted

← Bristol-Myers Squibb overview and focus areas